GI: esophagus

February 18, 2022

Prognosis impact of early adjuvant treatment discontinuation in stage III C

A pooled ACCENT/IDEA analysis demonstrates that for patients with stage III colorectal cancer treated with 6 months of oxaliplatin-based adjuvant chemotherapy, discontinuation of oxaliplatin while maintaining […]
February 18, 2022

KEYNOTE – 394: Pembrolizumab in second-line treatment of advanced HCC

The phase 3 study, KEYNOTE-394, demonstrated significant benefit of using pembrolizumab in combination with best supportive care for Asian patients with advanced hepatocellular carcinoma (HCC) in […]
February 18, 2022

Checkmate 9X8 addition the nivolumab in regimen the first -line treatment of metastatic colorectal cancer

Although the primary endpoint of this phase 2 study was not met, the addition of nivolumab to the standard first-line treatment for metastatic colorectal cancer showed […]
July 2, 2021

Final KEYNOTE 177 overall survival data for MSI-H/dMMR metastatic colorectal cancer

Pembrolizumab versus chemotherapy showed progression-free survival improvement in the second provisional analysis in patients with the tumor. The study continued until the final overall survival (OS) analysis, planned after 190 OS events […]
April 20, 2021

Combination of avelumab, trastuzumab and mFOLFOX6 demonstrates clinical activity in metastatic gastroesophageal adenocarcinoma with HER2 amplification

Trastuzumab is a monoclonal antibody directed to HER2, indicated in combination with chemotherapy in 20 to 30% metastatic esophageal or gastric adenocarcinomas that overexpress HER2. However, the […]